You are here: Home » News-CM » Companies » News
Business Standard

Cipla receives final ANDA approval for Esomeprazole for Oral Suspension

Capital Market 

Cipla announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Esomeprazole for Oral Suspension 10mg, 20mg and 40mg from the United States Food and Drug Administration (US FDA).

Cipla is the first company to file for the 10mg strength.

Cipla's Esomeprazole for Oral Suspension 10mg, 20mg and 40mg is AB-rated generic therapeutic equivalent version of AstraZeneca Pharmaceutical's Nexium.

It is a proton pump inhibitor indicated for the following: Treatment of gastroesophageal reflux disease (GERD). Risk reduction of NSAID-associated gastric ulcer. H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, March 26 2020. 09:31 IST